UK government clarifies process to verify a blood test for vCJD and releases Amorfix blinded panel results



    TSX: AMF

    TORONTO, Feb. 1 /CNW/ - Amorfix Life Sciences announced today that the
Expert Advisory Group of the British National Institute for Biological
Standards and Controls (NIBSC) has now established the process to verify the
performance of an acceptable blood test for vCJD. Based on the performance of
its EP-vCJD(TM) assay, Amorfix received and accepted an invitation from the
British government to further qualify the assay using British blood samples.
The NIBSC will provide blood samples from scrapie-infected sheep, normal human
controls and patients with vCJD.
    "It is an honour to be selected to access these precious vCJD patient
samples and move closer to securing the blood supply," said Dr. Neil Cashman,
Chief Scientific Officer for Amorfix. "Amorfix is ready to test these
samples."
    In addition, Amorfix received its EP-vCJD(TM) assay results from testing
a blinded panel of spiked human blood samples. These samples had been provided
by NIBSC as part of an ongoing tender process to supply testing kits for a
study of the prevalence of markers of vCJD in UK blood donors. Dr. Cashman,
will present these results at the 12th Annual Transmissible Spongiform
Encephalopathies conference in Baltimore, Maryland on February 11th.
    "With the positive results from the spiked human blood panel, Amorfix has
successfully completed the second step in the ongoing tender process to test
for the prevalence of vCJD in UK blood donors," said Dr. George Adams, Chief
Executive Officer of Amorfix. "We have manufactured the necessary kits to test
60,000 blood samples for prevalence testing."
    Recent evidence has suggested that people may be infected for decades
before showing signs of vCJD. The number of people who contracted the disease
by consuming BSE-positive products is unknown. To date, four people have been
officially reported to have been infected through blood transfusion from
donors who years later developed symptoms and died from vCJD. Thousands of
people who received vCJD-positive plasma fractions are currently being
monitored to determine how many have been infected. Blood transfusion services
in low-risk countries refuse to take blood from people who have lived in
high-risk countries, where BSE-positive cattle were prevalent, to prevent the
spread of the disease. A screening test for vCJD is needed urgently to prevent
the spread of vCJD through the blood transfusion services worldwide.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890